Author information
1
Meron Tesfay, MD, is Fellow in Gastroenterology, at Saint Louis University School of Medicine, St. Louis, Mo.
2
W. Joseph Goldkamp, MD, is Fellow in Gastroenterology, at Saint Louis University School of Medicine, St. Louis, Mo.
3
Brent A. Neuschwander-Tetri, MD, is a Professor of Internal Medicine at Saint Louis University School of Medicine, St. Louis, Mo.
Abstract
Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease that can progress to cirrhosis and hepatocellular carcinoma. This review provides brief answers to common questions clinicians may have about NASH. The diagnosis of NASHcurrently requires a liver biopsy, although non-invasive tests are being evaluated and may supplant liver biopsy in the near future. Treatment is focused on lifestyle modifications, with new medications currently in clinical trials.